Patents by Inventor Ann Maclaren

Ann Maclaren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of marizomib for the treatment of central nervous system (CNS) cancers
    Patent number: 11980606
    Abstract: The present disclosure relates to treatment of central nervous system (CNS) cancers (e.g., malignant glioma, glioblastoma, or CNS-multiple myeloma) using marizomib. The disclosure further relates to uses of synergistic combinations of marizomib with additional therapeutic agents such as bevacizumab, daratumumab, temozolomide, pomalidomide, and radiotherapy.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: May 14, 2024
    Assignee: Celgene International II Sàrl
    Inventors: Mohit Trikha, Nancy Levin, Ann Maclaren
  • USE OF MARIZOMIB FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) CANCERS
    Publication number: 20210169851
    Abstract: The present disclosure relates to treatment of central nervous system (CNS) cancers (e.g., malignant glioma, glioblastoma, or CNS-multiple myeloma) using marizomib. The disclosure further relates to uses of synergistic combinations of marizomib with additional therapeutic agents such as bevacizumab, daratumumab, temozolomide, pomalidomide, and radiotherapy.
    Type: Application
    Filed: November 10, 2020
    Publication date: June 10, 2021
    Inventors: Mohit Trikha, Nancy Levin, Ann MacLaren
  • Use of marizomib for the treatment of central nervous system (CNS) cancers
    Patent number: 10894036
    Abstract: The present disclosure relates to treatment of central nervous system (CNS) cancers (e.g., malignant glioma, glioblastoma, or CNS-multiple myeloma) using marizomib. The disclosure further relates to uses of synergistic combinations of marizomib with additional therapeutic agents such as bevacizumab, daratumumab, temozolomide, pomalidomide, and radiotherapy.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: January 19, 2021
    Assignee: Celgene International II Sarl
    Inventors: Mohit Trikha, Ann MacLaren, Nancy Levin
  • Use of marizomib for the treatment of central nervous system (CNS) cancers
    Patent number: 10857131
    Abstract: The present disclosure relates to treatment of central nervous system (CNS) cancers (e.g., malignant glioma, glioblastoma, or CNS-multiple myeloma) using marizomib. The disclosure further relates to uses of synergistic combinations of marizomib with additional therapeutic agents such as bevacizumab, daratumumab, temozolomide, pomalidomide, and radiotherapy.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: December 8, 2020
    Assignee: Celgene International II Sarl
    Inventors: Mohit Trikha, Ann MacLaren, Nancy Levin
  • ANTI-CD22 ANTIBODY-MAYTANSINE CONJUGATES, COMBINATIONS, AND METHODS OF USE THEREOF
    Publication number: 20190201541
    Abstract: The present disclosure provides methods for treating a cancer or resistant cancer with a combination of an anti-CD22 antibody-maytansine conjugate and one or more anti-cancer agents. The disclosure also encompasses methods for sensitizing a cancer with such combinations. Also provided are pharmaceutical compositions including such combinations.
    Type: Application
    Filed: December 11, 2018
    Publication date: July 4, 2019
    Inventor: Ann MACLAREN
  • USE OF MARIZOMIB FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) CANCERS
    Publication number: 20170348284
    Abstract: The present disclosure relates to treatment of central nervous system (CNS) cancers (e.g., malignant glioma, glioblastoma, or CNS-multiple myeloma) using marizomib. The disclosure further relates to uses of synergistic combinations of marizomib with additional therapeutic agents such as bevacizumab, daratumumab, temozolomide, pomalidomide, and radiotherapy.
    Type: Application
    Filed: June 1, 2017
    Publication date: December 7, 2017
    Inventors: Mohit Trikha, Ann MacLaren, Nancy Levin
  • CD23 BINDING MOLECULES AND METHODS OF USE THEREOF
    Publication number: 20090155255
    Abstract: The invention is based, at least in part, on the development of multivalent and stabilized forms of CD23 binding molecules and methods of use thereof for the treatment of immune cell disorders, including leukemias or lymphomas such as CLL.
    Type: Application
    Filed: September 29, 2008
    Publication date: June 18, 2009
    Applicant: Biogen Idec MA Inc.
    Inventors: Scott Glaser, Brian Robert Miller, Alexey Alexandrovich Lugovskoy, Stephen Demarest, Ann Maclaren, William B. Snyder